Biotransformations of oxaliplatin in rat blood in vitro

Journal of Biochemical and Molecular Toxicology

Volumn 13, Issue 3-4, 1999, Pages 159-169

  Luo, Feng R ^a,c   Wyrick, Steven D ^b   Chaney, Stephen G ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c RUTGERS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; OXALIPLATIN; PLATINUM COMPLEX;

ANIMAL; ARTICLE; BIOTRANSFORMATION; BLOOD; HALF LIFE TIME; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; RAT; WISTAR RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOTRANSFORMATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HALF-LIFE; MALE; ORGANOPLATINUM COMPOUNDS; RATS; RATS, WISTAR;

EID: 0032608728     PISSN: 10956670     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1099-0461(1999)13:3/4<159::aid-jbt6>3.0.co;2-c     Document Type: Article

References (20)

1. Kidani Y, Noji M, Tashiro T. Anti-tumor activity of platinum(II) complexes of 1,2-diaminocyclohexane isomers. Jpn Cancer Res 1980;71:637-643.
2. Levi F, Misset JL, Brienza S, Adam R, Metzger G, Itzakhi M, Caussanel JP, Kunstlinger S, Lecouturier S, Descorps-Declere A, Jasmin C, Bismuth H, Reinberg A. A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using ambulatory multichannel programmable pump. Cancer 1992;69:893-900.
3. Mathe G, Kidani Y, Segiguchi M, Eriguchi M, Fredj G, Peytavin G, Misset JL, Brienza S, De vassale S, Chenu E, Bourut C. Oxalatoplatinum or l-OPH, a third generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum. Biomed Pharmacother 1989;43:237-250.
4. Misset JL, Kidani Y, Gastiburu J. Oxalatoplatinum (l-OHP): experimental and clinical studies. In: Howel SB, editor. Platinum and other metal coordination complexes in cancer chemotherapy. New York: Plenum; 1991. pp 369-375.
5. Ozols RF. Ovarian cancer: new clinical approaches. Cancer Treat Rev 1991;18:77-83.
6. Weiss RB, Christian MC. New cisplatin analogues in development. Drugs 1993;46:360-377.
7. Extra JM, Espie M, Calvo F, Ferme C, Mignot L, Marty M. Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 1990;25:299-303.
8. Tashio T, Kawada Y, Sakurai Y, Kidani Y. Anti-tumor activity of a new platinum complex, oxalato-(trans-l-1,2-diaminocyclohexane)platinum(II): new experimental data. Biomed Pharmacother 1989;43:251-260.
9. Carfagna PF, Poma A, Wyrick SD, Holbrook DJ, Chaney SG. Comparisons of tetrachloro (d,l-trans)-1,2-diaminocyclohexaneplatinum(IV) biotransformations in the plasma of Fisher 344 rats at therapeutic and toxic doses. Cancer Chemother Pharmacol 1991;27:335-341.
10. Sakata M, Chaney SG, Spriggs DR. Possible correlation between ormaplatin biotransformations and neurotoxicity. Oncol Res 1995;7:67-71.
11. Pendyala L, Creaven PJ. In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Res 1993;53:5970-5976.
12. Luo FR, Yen TY, Wyrick S, Chaney SG. High performance liquid Chromatographic separation of biotransformation products of oxaliplatin formed in rat plasma in vitro. J Chromatog 13, in press.
13. Wyrick SD, Chaney SG. Tritated platinum anti-tumor agents containing the trans-(d,l)-1,2-diaminocyclohexane carrier ligand. J Labelled Compd Radiopharm 1987;25:349-357.
14. Yoshida M, Khokhar AR, Siddik Z. Axial ligand and alicyclic ring size modulate the activity and biochemical pharmacology of amine/cycoalkylamine-platinum(IV) complexes in tumor cells resistant to cis-diamminedichloroplatinum(II) or trans-1R, 2R-1S, 2S-diaminocyclohexanetetrachloroplatinum(IV). Cancer Res 1994;54:4691-4697.
15. Mauldin SK, Richard F, Plescia M, Wyrick SD, Sancar A, Chaney SG. High performance liquid Chromatographic separation of platinum complexes containing the 1,2-diaminocyclohexane carrier ligand. Anal Biochem 1986;157:129-143.
16. Mauldin SK, Gibbons G, Wyrick SD, Chaney SG. Intracellular biotransformation of platinum compounds with the 1,2-diaminocyclohexane carrier ligand in the L1210 cell line. Cancer Res 1988;48:5136-5144.
17. Balazova E, Hurbiska M, Ujhazy V. Comparison of the effectivity of two diaminocyclohexane Pt-complexes. Neoplasma (Bratisl.) 1985;32:537-541.
18. Chaney SG, Wyrick S, Till GK. In vitro biotransformations of tetrachloro-(d,l-trans)-1,2-diaminocyclohexaneplatinum(IV) (tetraplatin) in rat plasma. Cancer Res 1990;50:4539-4545.
19. Speer RJ, Ridgway M, Hall LM, Stewart DP. Preclinical testing of some cisplatin congeners as potential anti-tumor agents. J Clin Hematol Oncol 1980;10:9-13.
20. van der Vijgh WJF, Lelieveld P, Klein I, van Putten LM, Pinedo HM. Pharmacokinetics of five platinum compounds in dogs. In: Proceedings of the 4th international symposium on Platinum Coordination Complexes in Cancer Chemotherapy; 1980; Burlington, VT.